Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Gene Ther. 2013 Jan 31;20(8):807–815. doi: 10.1038/gt.2013.1

Figure 2. Genomic and infectious titers of VSV-G chimeric retroviral vectors.

Figure 2

Figure 2

Murine retroviral vector was packaged with the pCLPIT GFP vector plasmid, pCMV gag-pol, and pcDNA IVS VSV-G helper plasmid containing individual VSV-G variants. (a) Vector genomic titers were measured by real-time qPCR. (b) Transduction efficiencies on 293T cells were determined by flow cytometry analysis of retroviral vector mediated GFP expression. (c) Relative ratios of infectious titers to genomic titers (grey bars) titers and VSV-G ELISA data to genomic titers (black bars) of the retroviral vectors were calculated with the ratio of wild type VSV-G pseudotyped retroviral vector as 1, respectively. Error bars denote SD (n = 3). * and ** indicate statistical differences of P < 0.05 and P < 0.01, respectively, compared to infectivity of wild type VSV-G, as determined using an one-way ANOVA.